$3.00 0.00 (%) Threshold Pharmaceuticals - NASDAQ

Oct. 21, 2014 | 04:00 PM

Partner Headlines

  1. Threshold Pharma Says Phase 3 Trial of TH-302 in Patients with Advanced Soft Tissue Sarcoma Will Continue as Planned

    Benzinga | Sep. 22, 2014 | 08:04AM EST
  2. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 14:34PM EST
  3. Apple Unveils Watch, Larger iPhones; Francesca's Shares Drop After Downbeat Results

    Benzinga | Sep. 9, 2014 | 15:58PM EST
  4. Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation

    Benzinga | Sep. 5, 2014 | 09:43AM EST
  5. Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma

    Benzinga | Jul. 9, 2014 | 07:01AM EST
  6. US Stock Futures Flat After Record Close

    Benzinga | Nov. 22, 2013 | 07:09AM EST
  7. Threshold Pharma Reports New Clinical Data on TH-302, Says One CR, Two Partial

    Benzinga | Nov. 22, 2013 | 07:06AM EST
  8. Threshold New Data on Combination of TH-302 and Avastin in Recurrent Glioblastoma to be Presented at WFNO/SNO

    Benzinga | Nov. 11, 2013 | 07:29AM EST
  9. Threshold Pharma Reports TH-302 Data Will Be Presented at ASH

    Benzinga | Nov. 7, 2013 | 09:01AM EST
  10. Threshold Pharma Reports Early Clinical Data for Combining TH-302, Says Trial Achieved Partial Response Rate 12%, Stable Disease Rate 64%

    Benzinga | Oct. 21, 2013 | 07:23AM EST
  11. Threshold Pharmaceuticals Initiates Phase 2 Study of TH-302 in Patients With Advanced Melanoma

    Benzinga | Aug. 8, 2013 | 07:09AM EST
  12. UPDATE: Piper Jaffray Initiates Threshold Pharmaceuticals at Neutral Ahead of Pivotal Data

    Benzinga | Jan. 18, 2013 | 01:08AM EST
  13. Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 2, 2012 | 13:08PM EST
  14. Threshold Pharmaceuticals Announces Agreement With U.S. FDA on a Special Protocol Assessment for Planned Phase 3 Trial of TH-302

    Benzinga | Oct. 16, 2012 | 01:35AM EST
  15. Maxim Group Reiterates Buy Rating, $10 PT on Threshold Pharmaceuticals

    Benzinga | Oct. 1, 2012 | 06:21AM EST
  16. UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential

    Benzinga | Sep. 20, 2012 | 07:35AM EST
  17. Threshold Pharmaceuticals (THLD) Loses 20.5% on Mixed Data from Drug Trial

    MarketIntelligenceCenter | Sep. 17, 2012 | 12:54PM EST
  18. Morning Market Losers

    Benzinga | Sep. 17, 2012 | 03:56AM EST
  19. FROM EARLIER: Threshold Pharma Says Study of TH-302 Demonstrated a Statistically Significant 63% Improvement in Patients

    Benzinga | Sep. 17, 2012 | 03:31AM EST
  20. Eli Lilly &, Limited Brands Included in Stocks Up on High Volume Friday

    FoxBusiness | Aug. 24, 2012 | 06:33AM EST
  21. Threshold Pharmaceuticals Appoints Laura G. Hansen, Ph.D., Senior Director, Corporate Communications

    Benzinga | Aug. 16, 2012 | 01:30AM EST
  22. Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 6, 2012 | 03:19AM EST
  23. Benzinga's Top Initiations

    Benzinga | Jul. 10, 2012 | 01:28AM EST
  24. Bullish Brokerage Note Propels Threshold Pharmaceuticals' Call Volume

    SchaeffersResearch | Apr. 3, 2012 | 10:33AM EST
  25. Threshold Pharma Pops 18% on Positive Quarterly Results

    Benzinga | Mar. 8, 2012 | 03:14AM EST
  26. Nine ETFs Trading Near 52-Week Highs

    Benzinga | Mar. 4, 2012 | 06:11AM EST
  27. These Small-Cap Stocks Have Already More Than Doubled In 2012!

    Benzinga | Feb. 23, 2012 | 08:47AM EST
  28. Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

    Benzinga | Feb. 21, 2012 | 00:14AM EST
  29. Benzinga's Microcap Movers for Friday February 3, 2012

    Benzinga | Feb. 5, 2012 | 04:39AM EST
  30. Financial Breakfast: Morning News Summary for February 3, 2012

    Benzinga | Feb. 3, 2012 | 00:21AM EST
  31. Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias

    Benzinga | Dec. 13, 2011 | 23:51PM EST
Trading Center